Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05761366

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Malignancy Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Chaoyang, 100029, China

Location status: Recruiting

Location contact

Xin Cheng, MD

CONTACT

[email protected]

15120002998

About this study

Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed PSMA positive-expressing tumors (including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.) , to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.
  • Age is 18 or older; No gender limitation.
  • Signed the informed consent.
  • Willing and able to cooperate with all projects in this study.

Exclusion criteria

  • Patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc
  • Claustrophobia.
  • Pregnant or lactation women.
  • Received experimental drug or device within 1 month.

Treatment and study plan

Al18F-PSMA-BCH PET/CT

Drug

Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.

Other names: 18F-Thretide PET/CT

Primary outcomes

  1. Diagnostic value

    Time frame: through study completion, an average of 1 year

    Sensitivity and Specificity of 18F-PSMA PET / CT for the diagnosis of Prostate Specific Membrane Antigen Positive Tumor

Study contacts

Contact information is provided by the study sponsor or research team.

Guozhu Hou, MD

CONTACT

[email protected]

15611145656

Xin Cheng, MD

CONTACT

[email protected]

15120002998

Sponsors and collaborators

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Other

Registry information

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Mar 9, 2023
Registry last updated
Dec 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.